SCHEMBL3472268

SCHEMBL3472268

O=C(NCc1ccccc1F)c1ccc(-c2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.51
NR1H2 P55055 2/20 0.51
NR1H3 Q13133 2/20 0.51
CNR1 P21554 1/20 0.50
CACNA1G O43497 1/20 0.49
CACNA1H O95180 1/20 0.49
TRPV1 Q8NER1 2/20 0.47
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NR3C2 P08235 1/20 0.45
LMNA P02545 2/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472749 0.93 SMN1; SMN2 (0.54) RXRANR1H2NR1H3TRPV1TP53
SCHEMBL3474104 0.92 RXRA (0.49) RXRANR1H2NR1H3CNR1TRPV1
SCHEMBL3472003 0.91 TRPV1 (0.50) RXRANR1H2NR1H3TRPV1TP53
SCHEMBL3474743 0.91 EPHX2 (0.54) RXRANR1H2NR1H3TP53SMN1; SMN2
SCHEMBL3475775 0.89 RXRA (0.56) RXRANR1H2NR1H3CNR1TRPV1
SCHEMBL3475206 0.88 CNR1 (0.52) RXRANR1H2NR1H3CNR1TRPV1
SCHEMBL3473186 0.88 HTT (0.53) RXRANR1H2NR1H3SMN1; SMN2HDAC1
SCHEMBL3472901 0.86 RXRA (0.49) RXRANR1H2NR1H3CACNA1GCACNA1H
SCHEMBL3474538 0.86 RXRA (0.52) RXRANR1H2NR1H3CNR1NR3C2
SCHEMBL3471475 0.86 IDH1 (0.53) RXRANR1H2NR1H3NR3C2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.